Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their pipelines ahead of upcoming patent losses. The surge appears broader and more durable than just a rebound to pre-COVID years, at least three analysts, four investors and a banker told Reuters. The total biotech M&A deal value in the first quarter has already hit $84 billion, up from $44.4 billion a year earlier, the strongest start to a year since 2019, when the deals reached $147.7 billion, Dealogic data showed.
Read the full article: Big Pharma M&A Set for Mega Year as Patent Expiries Drive Deal Urgency //
Source: https://www.reuters.com/legal/transactional/big-pharma-ma-set-mega-year-patent-expiries-drive-deal-urgency-2026-05-01/